Livagen vs Thymalin
Comparison of Livagen (Low evidence) and Thymalin (Moderate evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Livagen
Dossier overview
Thymalin
Dossier overview
Overview
Livagen and Thymalin are both studied in the peptide research space.
Livagen: A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression.
Thymalin: A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation.
Evidence Comparison
| Aspect | Livagen | Thymalin |
|---|---|---|
| Evidence Level | Low | Moderate |
| Human Studies | 2 | 8 |
| Preclinical Studies | 8 | 22 |
| Total Sources | 12 | 30 |
Key Differences
| Aspect | Livagen | Thymalin |
|---|---|---|
| Category | Other | Immune |
| Evidence Strength | Low | Moderate |
| Total Sources | 12 | 30 |
| Human Studies | 2 | 8 |
Summary
- Livagen: Low evidence with 12 total sources (2 human)
- Thymalin: Moderate evidence with 30 total sources (8 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.